Claes Malmberg: CIRCLE, Lund University, Postal: PO Box 117, Sölvegatan 16, SE-22100 Lund, Sweden
Abstract: This study investigates the determinants of R&D expenditures in the Swedish pharmaceutical industry from the 1960s to the mid 1990s. Various proxies for the rate of return of R&D (e.g. expected profit, sales and R&D productivity) as well as the availability of internal funding (proxied by past cash flows) have been used as explanatory variables in time series regressions. Past cash flow comes out as significant in regressions both at industry level and at firm level (made for each of the two largest companies). Another factor that is significant in most cases is expected sales. However, productivity of the R&D process does not seem to influence R&D expenditures. A comparison of these conclusions with studies of the pharmaceutical industries in countries with different financial systems; the US (with a market based financial system) and Japan (with a more bank based financial system) shows that Sweden (also leaning towards a bank based financial system) has the insensitivity to R&D productivity in common with Japan. This may be interpreted as these industries’ are taking a ‘longer term view’ on their research than the US’. The sensitivity to cash flow, however, is possibly more pronounced in Sweden than in Japan and suggests an important role of internal financing of R&D.
23 pages, June 1, 2008
Full text files
Questions (including download problems) about the papers in this series should be directed to Torben Schubert ()
Report other problems with accessing this service to Sune Karlsson ().
This page generated on 2018-01-23 23:35:04.